<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553458</url>
  </required_header>
  <id_info>
    <org_study_id>22/09/2020</org_study_id>
    <nct_id>NCT04553458</nct_id>
  </id_info>
  <brief_title>Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      EASL and mRECIST criteria differ from each other in terms of the number of target lesions&#xD;
      (all versus &lt; = 2) and calculation method (bidimensional versus unidimensional). Therefore,&#xD;
      the investigators aimed to retrospectively analyze and compare the clinical outcomes among&#xD;
      patients with hepatocellular carcinoma who were treated with different modalities of therapy&#xD;
      according to the BCLC classification, and detect the possible predictors of post-treatment&#xD;
      outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      EASL and mRECIST criteria differ from each other in terms of the number of target lesions&#xD;
      (all versus &lt; = 2) and calculation method (bidimensional versus unidimensional). Therefore,&#xD;
      the investigators aimed to retrospectively analyze and compare the clinical outcomes among&#xD;
      patients with hepatocellular carcinoma (HCC) who were treated with different modalities of&#xD;
      therapy according to the BCLC classification, and detect the possible predictors of&#xD;
      post-treatment outcomes.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      This work was conducted at the departments of tropical medicine and gastroenterology,&#xD;
      internal medicine, and general surgery. This study included patients that matched our&#xD;
      eligibility criteria for a period of five years started from June 2015 to May 2020. The study&#xD;
      purpose was to retrospectively analyze the clinical outcomes among patients with HCC who were&#xD;
      treated with different modalities of therapy according to the BCLC classification, and detect&#xD;
      the possible predictors of post-treatment favorable outcomes. The data of the patients were&#xD;
      extracted and retrospectively reviewed from the patients' records and the databases of both&#xD;
      hospitals (SUH and SOI).&#xD;
&#xD;
      During the period of recruitment, 407 patients diagnosed with HCC admitted to our departments&#xD;
      and followed-up attending outpatient clinics, Sohag University Hospitals, over a 5 years&#xD;
      period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CURE (Number of patients cured completely from the disease)</measure>
    <time_frame>one-year</time_frame>
    <description>the HCC is treated (disappearance of all lesions)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STABLE Disease (Number of patients with neither progression nor cure from the disease)</measure>
    <time_frame>one-year</time_frame>
    <description>NONE of the other outcomes' criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PROGRESSIVE((Number of patients with progression of the disease) (measured by follow-up CT scans, increase in size, appearance of new intratumoral lesions, or appearance of new lesions</measure>
    <time_frame>one-year</time_frame>
    <description>increase in size - appearance of new intratumoral lesions - new lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DEATH (Number of patients died from the disease)</measure>
    <time_frame>one-year</time_frame>
    <description>Mortality rate</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">407</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Favorable outcome</arm_group_label>
    <description>Cure or stable disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unfavorable outcome</arm_group_label>
    <description>Progressive (deteriorate/Recurrence) or Death</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
    <description>Radiofrequency ablation of the tumour</description>
    <arm_group_label>Favorable outcome</arm_group_label>
    <arm_group_label>Unfavorable outcome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trance-arterial chemoembolization</intervention_name>
    <description>Trance-arterial chemotherapy</description>
    <arm_group_label>Favorable outcome</arm_group_label>
    <arm_group_label>Unfavorable outcome</arm_group_label>
    <other_name>transcatheter arterial chemoembolization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver resection</intervention_name>
    <description>non-anatomical or anatomical liver resection</description>
    <arm_group_label>Favorable outcome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Combined radiofrequency ablation + percutaneous ethanol injection</intervention_name>
    <description>combined therapy</description>
    <arm_group_label>Favorable outcome</arm_group_label>
    <arm_group_label>Unfavorable outcome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Percutaneous ethanol injection</intervention_name>
    <description>Percutaneous ethanol injection of HCC</description>
    <arm_group_label>Favorable outcome</arm_group_label>
    <arm_group_label>Unfavorable outcome</arm_group_label>
    <other_name>ETHANOL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systemic chemotherapy</intervention_name>
    <description>Systemic chemotherapy</description>
    <arm_group_label>Unfavorable outcome</arm_group_label>
    <other_name>MIXED</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib</description>
    <arm_group_label>Unfavorable outcome</arm_group_label>
    <other_name>NEXAVAR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Viscum</intervention_name>
    <description>Viscum for HCC</description>
    <arm_group_label>Unfavorable outcome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symptomatic treatment</intervention_name>
    <description>Symptomatic treatment</description>
    <arm_group_label>Unfavorable outcome</arm_group_label>
    <other_name>SUPPORTIVE</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This work was conducted at the departments of tropical medicine and gastroenterology,&#xD;
        internal medicine, and general surgery. This study included patients that matched our&#xD;
        eligibility criteria for a period of five years started from June 2015 to May 2020. The&#xD;
        study purpose was to retrospectively analyze the clinical outcomes among patients with HCC&#xD;
        who were treated with different modalities of therapy according to the BCLC classification,&#xD;
        and detect the possible predictors of post-treatment favorable outcomes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients&#xD;
&#xD;
          -  with hepatocellular carcinoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severely-ill patients&#xD;
&#xD;
          -  With other system comorbidities,&#xD;
&#xD;
          -  presence of extrahepatic metastasis,&#xD;
&#xD;
          -  patients who dropped from the follow-up list after treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emad A. Ahmed, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sohag University</affiliation>
  </overall_official>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 5, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Emad Ali Ahmed Ali</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>Hepatoma</keyword>
  <keyword>primary liver tumours</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

